Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain.
Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain.
复制标题
DOI：
10.1186/s42238-023-00179-8
复制
发表时间：
2023-03-30
影响因子：
3.7
通讯作者：
Murnane, Kevin Sean
中科院分区：
文献类型：
--
作者：
Hall, Nicole;James, Bradie;Bhuiyan, Mohammad Alfrad Nobel;Crane, Erin;Falgout, Carlie;Murnane, Kevin Sean
大麻二酚（CBD）是一种潜在的疼痛治疗药物。然而，缺乏对其耐受性和有效性的研究，特别是在特殊人群中。前精英运动员是一个特殊的人群，他们既容易受到慢性疼痛的影响，也受过高度训练，善于评估药物耐受性问题。目前的开放标签初步研究的目的是评估CBD在该人群中的耐受性。回顾性分析了来自20名个人的去识别数据，这些人以前都是美国/美式足球，田径或篮球的专业运动员，职业生涯从4到10年不等。参与者接受局部CBD（10 mg，每日两次，由受控分配器）治疗急性下肢损伤引起的慢性疼痛。在6周的研究期间，通过自我报告收集耐受性评估和疼痛、疼痛相关残疾和日常生活活动的次要分析。资料以描述性统计、配对t检定及线性回归分析。70%的参与者完成了这项研究。在完成研究的个体中，50%的人报告了轻微的不良反应，其中没有一个需要医疗护理，50%的人没有报告任何不良反应。最常报告的影响是皮肤干燥（43%的研究完成者）和皮疹（21%的研究完成者），这些影响迅速消退。自我报告的疼痛水平（摄入平均值为3.5 ± 0.29;退出平均值为1.7 ± 0.23; P < 0.001）和疼痛相关残疾（包括家庭和家庭责任、生命支持活动、职业活动、娱乐活动、自我护理、性功能和社会活动）均有显著改善（均P < 0.001）。据我们所知，这是第一项评估精英运动员CBD治疗的研究，这些运动员容易受到致残性损伤。该人群对CBD的局部给药耐受良好，仅导致轻微的不良反应。由于精英运动员的职业生活，他们接受了训练和调整，以评估自己的身体，这一人群可能会发现耐受性问题。然而，这项研究仅限于方便的样本和自我报告的数据。这些初步研究结果值得在精英运动员的随机和对照研究中进一步研究局部CBD。
Cannabidiol (CBD) is a potential therapeutic for pain management. Yet, there exists a dearth of studies of its tolerability and efficacy, especially in special populations. Former elite athletes are a special population both susceptible to chronic pain and also highly trained and attuned to assess medication tolerability concerns. The purpose of the present open-label pilot study was to assess the tolerability of CBD in this population. Retrospective analysis was conducted in deidentified data from 20 individuals who were all previously professional athletes in US/American football, track and field, or basketball, with careers ranging from 4 to 10 years. Participants received topical CBD (10 mg twice daily by controlled dispenser) for chronic pain resulting from acute lower extremity injuries. Assessments of tolerability and secondary analyses of pain, pain-related disability, and activities of daily living were collected by self-report over the 6-week study period. Data were analyzed by descriptive statistics, pairwise t-test, and linear regression. Seventy percent of participants completed the study. Of the individuals who completed the study, 50% reported minor adverse effects, none of which required medical attention, and 50% did not report any adverse effects. The mostly commonly reported effects were skin dryness (43% of study completers) and skin rash (21% of study completers), which rapidly resolved. There was a significant improvement in self-reported pain levels (intake mean 3.5 ± 0.29; exit mean 1.7 ± 0.23; P < 0.001) and pain-related disability, including family and home responsibilities, life support activities, occupational activities, recreational activities, self-care, sexual function, and social activities (all P < 0.001). To the best of our knowledge, this is the first study to assess CBD treatment in elite athletes, who are disproportionally susceptible to disabling injuries. Topical administration of CBD was tolerated well by this population and resulted in only minor adverse effects. As elite athletes are trained and attuned to assess their own bodies due to their professional lives, this population is likely to detect tolerability concerns. However, this study was limited to a convenience sample and self-reported data. These pilot findings warrant further study of topical CBD in randomized and controlled studies of elite athletes.